32 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | GIBBS, TERRA C | 1635 | Non-Final OA | Apr 16, 2024 |
| 18427072 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | VANHORN, ABIGAIL LOUISE | 1636 | Final Rejection | Jan 30, 2024 |
| 18385005 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS | MCKILLOP, JOHN CHARLES | 1637 | Non-Final OA | Oct 30, 2023 |
| 18382562 | METHODS OF TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Non-Final OA | Oct 23, 2023 |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | Final Rejection | Oct 03, 2023 |
| 18324191 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | TRAN, CHRISTINA L | 1637 | Non-Final OA | May 26, 2023 |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Non-Final OA | Apr 19, 2023 |
| 18301089 | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | CHONG, KIMBERLY | 1636 | Non-Final OA | Apr 14, 2023 |
| 18299220 | METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS | GIBBS, TERRA C | 1635 | Non-Final OA | Apr 12, 2023 |
| 18247314 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | GIBBS, TERRA C | 1635 | Non-Final OA | Mar 30, 2023 |
| 18125167 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Non-Final OA | Mar 23, 2023 |
| 18044401 | IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 10 (GRB10) OR GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER | ARIETI, RUTH SOPHIA | 1635 | Non-Final OA | Mar 08, 2023 |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 1637 | Non-Final OA | Feb 09, 2023 |
| 18007007 | ATXN2 IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING ATXN2-ASSOCIATED NEURODEGENERATIVE DISEASES | WHITEMAN, BRIAN A | 1636 | Non-Final OA | Jan 26, 2023 |
| 18015202 | Circular siRNAs | TRAN, CHRISTINA L | 1637 | Non-Final OA | Jan 09, 2023 |
| 18001813 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | Non-Final OA | Dec 14, 2022 |
| 18077271 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | GIBBS, TERRA C | 1635 | Non-Final OA | Dec 08, 2022 |
| 17982819 | CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS | ANGELL, JON E | 1637 | Non-Final OA | Nov 08, 2022 |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 1637 | Final Rejection | Oct 27, 2022 |
| 17995568 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MEYERING, SHABANA SHABBEER | 1635 | Non-Final OA | Oct 05, 2022 |
| 17956882 | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | GIBBS, TERRA C | 1635 | Non-Final OA | Sep 30, 2022 |
| 17995035 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | Non-Final OA | Sep 29, 2022 |
| 17945151 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | HUDSON, AMY ROSE | 1636 | Non-Final OA | Sep 15, 2022 |
| 17794637 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | Final Rejection | Jul 22, 2022 |
| 17779706 | SYNTHESIS OF 3 -RNA OLIGONUCLEOTIDES | CREWS, JARET JAMES | 1691 | Non-Final OA | May 25, 2022 |
| 17736251 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | VANHORN, ABIGAIL LOUISE | 1636 | Non-Final OA | May 04, 2022 |
| 17774477 | EXTRAHEPATIC DELIVERY | VANHORN, ABIGAIL LOUISE | 1636 | Final Rejection | May 04, 2022 |
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | Non-Final OA | Mar 01, 2022 |
| 17672771 | NEUROFILAMENT LIGHT CHAIN (NFL) AS A BIOMARKER FOR TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY | TRAN, CHRISTINA L | 1637 | Final Rejection | Feb 16, 2022 |
| 17668917 | ENDOSOMAL CLEAVABLE LINKERS | VANHORN, ABIGAIL LOUISE | 1636 | Final Rejection | Feb 10, 2022 |
| 17668413 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALLEN, SARAH ELIZABETH | 1637 | Non-Final OA | Feb 10, 2022 |
| 17314909 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SHIN, DANA H | 1635 | Final Rejection | May 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial